VANI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vivani Medical Inc (VANI) is not a strong buy for a beginner investor with a long-term focus at this time. While the stock has shown a pre-market price increase of 6.11%, there are no significant positive catalysts, strong technical signals, or favorable financial performance to justify an immediate buy decision. The lack of recent news, weak financials, and absence of strong trading signals suggest holding off on investment until more favorable conditions arise.
The MACD is positive and contracting, indicating a potential weakening of bullish momentum. RSI is neutral at 57.009, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 1.263, with resistance at 1.461 and support at 1.064.
Pre-market price increase of 6.11%. Analyst maintains a Buy rating, citing the potential of NPM-139 as a unique product in its market.
Weak financial performance with negative net income (-$6.63M) and declining EPS (-18.18% YoY). No recent news or significant trading trends from insiders or hedge funds. No recent congress trading data.
In Q4 2025, revenue remained at $0, with no growth YoY. Net income improved slightly by 9.64% YoY but remains negative at -$6.63M. EPS dropped by 18.18% YoY to -0.09, indicating worsening profitability.
H.C. Wainwright analyst Yi Chen lowered the price target from $4 to $3.50 while maintaining a Buy rating, citing an increased share count. The analyst remains optimistic about the potential of NPM-139 but acknowledges the challenges reflected in the lowered target.
